In vivo最新文献_第5页

Effect of Nutritional Index on Lenvatinib Treatment Retention Rates in Unresectable Hepatocellular Carcinoma.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13904

Ryosuke Wakamatsu, Mizuki Nakayama, Ayaka Wakamatsu, Yuki Yamashita, Hiroo Suto, Miki Katsuragawa, Akio Shibanami, Kazuya Hiura

{"title":"Effect of Nutritional Index on Lenvatinib Treatment Retention Rates in Unresectable Hepatocellular Carcinoma.","authors":"Ryosuke Wakamatsu, Mizuki Nakayama, Ayaka Wakamatsu, Yuki Yamashita, Hiroo Suto, Miki Katsuragawa, Akio Shibanami, Kazuya Hiura","doi":"10.21873/invivo.13904","DOIUrl":"10.21873/invivo.13904","url":null,"abstract":"Background/aim: Several studies have reported the association between lenvatinib (LEN) treatment and nutritional indices. However, no study has used multiple nutritional indices or reported their changes during treatment. This study aimed to clarify the association between LEN treatment and nutritional status.Patients and methods: Patients with hepatocellular carcinoma (n=103) treated with LEN were divided into two groups, namely normal and poor nutritional groups, using the Controlling Nutritional Status (CONUT) score, Onodera-Prognostic Nutritional Index (O-PNI), modified Glasgow Prognostic Score (mGPS), and Geriatric Nutritional Risk Index (GNRI). Treatment retention rates were then compared between the two groups. Additionally, changes in nutritional indices from the start of treatment to the end of the observation period or treatment were analyzed to determine their relationship with treatment continuation.Results: Patients with normal nutrition according to the CONUT score, O-PNI, mGPS, and GNRI had a significantly higher rate of treatment retention than those with poor nutrition. Furthermore, both a normal CONUT score and mGPS indicated a lower likelihood of discontinuation due to adverse events. Patients in whom treatment was continued were significantly more likely to maintain or improve their CONUT score.Conclusion: Maintaining or restoring a normal nutritional status is important to ensure continued treatment with LEN. Both the combination of the CONUT score and mGPS at the start of LEN treatment, and the CONUT score during treatment, are useful indicators of nutritional status.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"988-999"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of Risedronate Analog on Extraction Socket Healing in Mice.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13870

Moeka Kasagawa, Yuichi Mine, Mizuho Sano, Yukinaga Kurokui, Ayano Ueda, Masato Kaku, Hiroki Nikawa, Takeshi Murayama

{"title":"Analysis of Risedronate Analog on Extraction Socket Healing in Mice.","authors":"Moeka Kasagawa, Yuichi Mine, Mizuho Sano, Yukinaga Kurokui, Ayano Ueda, Masato Kaku, Hiroki Nikawa, Takeshi Murayama","doi":"10.21873/invivo.13870","DOIUrl":"10.21873/invivo.13870","url":null,"abstract":"Background/aim: Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse effect associated with anti-resorptive medications like nitrogen-containing bisphosphonates (N-BPs), particularly zoledronate (ZOL). This study aimed to investigate whether a BP analog with high bone affinity but minimal anti-resorptive activity, NE-58051, could induce MRONJ-like lesions in a mouse model.Materials and methods: Female C57BL/6J mice (n=6 per group) were administered ZOL (250 μg/kg intravenously, twice weekly) for one or two weeks, or NE-58051 (250 μg/kg intravenously, twice weekly) for two weeks. Two weeks after initiation of study, the bilateral first molars were extracted. Mice were euthanized after a total duration of four weeks. Histological assessments evaluated necrotic bone area and osteoclast activity at extraction sites. Serum tartrate-resistant acid phosphatase isoform 5b (TRAcP-5b) levels were measured.Results: Mice treated with ZOL for two weeks exhibited significant increases in empty osteocytic lacunae and necrotic bone area compared to the saline group, indicating the development of MRONJ-like lesions. NE-58051-treated mice did not show significant differences in necrotic bone area or osteoclast activity compared to controls. No significant differences were observed in serum TRAcP-5b levels among all groups.Conclusion: High bone affinity without potent inhibition of bone resorption does not induce MRONJ-like lesions in mice. These findings suggest that the potent anti-resorptive activity of N-BPs is a key factor in MRONJ development, highlighting the importance of bone turnover suppression in the pathogenesis of this condition.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"648-655"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Participant Perspectives on Pulse-Echo Ultrasound Technology vs. Dual Energy X-Ray Absorptiometry (DXA): A Comparative Study.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13895

Abdulkareem Algahtani, Mohammed Asiri, Kinan Mokbel, Robert Meertens, Jon Fulford, William David Strain, Karen Knapp

{"title":"Participant Perspectives on Pulse-Echo Ultrasound Technology vs. Dual Energy X-Ray Absorptiometry (DXA): A Comparative Study.","authors":"Abdulkareem Algahtani, Mohammed Asiri, Kinan Mokbel, Robert Meertens, Jon Fulford, William David Strain, Karen Knapp","doi":"10.21873/invivo.13895","DOIUrl":"10.21873/invivo.13895","url":null,"abstract":"Background/aim: Osteoporosis is a global health concern causing severe fractures, and timely diagnosis with thorough bone assessment is crucial for effective management. Diagnostic tools such as Bindex® (a novel ultrasound-based diagnostic technology) and DXA (X-ray-based) play a key role in identifying and assessing bone conditions. This study aimed to evaluate and compare these two approaches' overall acceptability, comfort, and preference. Feelings of pain and perceptions regarding the scan length during the Bindex® scanning procedure were also assessed.Patients and methods: Two diagnostic imaging tools were used in this comparative study: Bindex® (pulse-echo ultrasound technology) and DXA (X-ray technology). A bespoke questionnaire was employed to gather the participants' responses, which were coded numerically, and data were analysed statistically.Results: Despite minor discomfort associated with the gel application, Bindex® received significantly higher acceptability and comfort ratings than DXA, with many participants preferring its non-ionising radiation. Both methods were generally well-received, though some favoured DXA for not requiring gel.Conclusion: In addition to enhancing diagnostic workflows, we demonstrated that Bindex® scans can improve patient satisfaction. This study emphasised the importance of innovating medical imaging diagnostic tools to prioritise patient acceptability and comfort.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"909-916"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prolonged Viral Shedding of SARS-CoV-2 in Patients With Underlying Haemato-oncological Disease.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13887

Alexander Casimir Angleitner, Lena Levien, Judith Büntzel

{"title":"Prolonged Viral Shedding of SARS-CoV-2 in Patients With Underlying Haemato-oncological Disease.","authors":"Alexander Casimir Angleitner, Lena Levien, Judith Büntzel","doi":"10.21873/invivo.13887","DOIUrl":"10.21873/invivo.13887","url":null,"abstract":"Background/aim: Case reports describe prolonged COVID19 shedding in patients with malignant hematological disease. Similarly, we observed extended viral shedding in hemato-oncological patients (HP) at our SARS-CoV-2 unit. This raises the question of whether HP are more susceptible to prolonged SARS-CoV-2 shedding and which aspects of immunosuppression contribute to this phenomenon.Patients and methods: Data from HP treated at a single center between 02/2022 and 02/2023 were retrospectively analyzed. Overall, 47 HP with a positive SARS-CoV-2 PCR test were included. Additional data on 16 HP were retrieved from literature. The duration of SARS-CoV-2 positivity (t[SARS+]) was compared between subgroups with different diagnoses, immune status, and HP with and without medical treatment of SARS-CoV-2.Results: t[SARS+] of HP was 47 days [interquartile range (IR)=25-95] and 12 HP (19%) were still positive by the end of the follow-up. In our cohort, four HP died while still shedding SARS-CoV-2 [t[SARS+]=47 days (IR=33.5-86)]. Different oncological diagnoses did not influence t[SARS+]. HP under steroids had a significantly longer average t[SARS+] (108 days vs. 45 days; p=0.016). HP with B cell depletion/T cell depletion and leukopenia were found to require more time to test negative for SARS-CoV-2 (p Logrank <0.05). Vaccinated HP had a significantly shorter duration of viral shedding (vaccinated 35.5 days vs. not vaccinated 86 days; p Logrank <0.01).Conclusion: Prolonged viral shedding is a common occurrence in HP. Our data illustrate that HP under immune suppression show a significantly longer t[SARS+]. Furthermore, we demonstrate that vaccination influences the length of viral shedding.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"844-850"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Could Transcervical Radiofrequency Ablation Become a Therapy Option for Focal Adenomyosis?

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13901

Elvin Piriyev, Angelika Dieter, Sven Schiermeier, Stefan Renner, Thomas Römer

{"title":"Could Transcervical Radiofrequency Ablation Become a Therapy Option for Focal Adenomyosis?","authors":"Elvin Piriyev, Angelika Dieter, Sven Schiermeier, Stefan Renner, Thomas Römer","doi":"10.21873/invivo.13901","DOIUrl":"10.21873/invivo.13901","url":null,"abstract":"Background/aim: Adenomyosis is a common gynecological disease characterized by the presence of ectopic endometrial tissue (endometrial stroma and glands) within the myometrium. It is classified into two main types: diffuse and focal. The aim of this study was to present the outcomes of patients with focal adenomyosis following treatment with transcervical radiofrequency ablation.Patients and methods: This was a retrospective analysis of patients treated with the Sonata® System. A total of 574 cases were analyzed, all performed at two centers in Germany: Academic Hospital Cologne Weyertal and Hospital Böblingen.Results: Thirty patients with focal adenomyosis were treated with transcervical radiofrequency ablation. All surgeries were performed without any complications. The mean surgery's time was 30.7 minutes, while the mean ablation time was 8.5 minutes. At the time of this report, 27 patients had returned for follow-up. 89% of patients reported improvement in their symptoms. No patient reported a worsening of their symptoms. The procedure reduced the average focal lesion size from 4.4 cm to 2.8 cm. No postoperative complications were observed. All patients reported satisfaction with the procedure.Conclusion: Transcervical radiofrequency ablation appears to be an effective approach for treating adenomyosis. The Sonata® System, in particular, offers notable advantages, making it a potentially valuable alternative to conventional procedures like hysterectomy and tissue excision. This minimally invasive approach preserves the uterus, providing a less invasive and more patient-centered treatment option for adenomyosis.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"961-968"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and Feasibility of Outpatient Zolbetuximab Administration in Community Cancer Care: A Mixed-methods Analysis.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13900

Erina Yakuwa, Yuko Shoji, Takashi Oizumi, Yuka Kobayashi, Taichi Motoishi, Takuto Katagiri, Shuhei Suzuki

{"title":"Safety and Feasibility of Outpatient Zolbetuximab Administration in Community Cancer Care: A Mixed-methods Analysis.","authors":"Erina Yakuwa, Yuko Shoji, Takashi Oizumi, Yuka Kobayashi, Taichi Motoishi, Takuto Katagiri, Shuhei Suzuki","doi":"10.21873/invivo.13900","DOIUrl":"10.21873/invivo.13900","url":null,"abstract":"Background/aim: Zolbetuximab, a CLAUDIN18.2-targeted antibody, traditionally requires inpatient administration due to potential adverse events. This study evaluated the safety and feasibility of outpatient administration in a community cancer center setting.Patients and methods: Five patients with CLAUDIN18.2-positive advanced gastric cancer received outpatient zolbetuximab between July and November 2024. We implemented a structured protocol incorporating standardized premedication, hospital-pharmacy collaboration, and comprehensive monitoring. Safety, treatment adherence, economic outcomes, and patient experiences were analyzed using mixed methods.Results: No grade 3 or higher adverse events were observed, with mild nausea being the most common toxicity. Treatment adherence was high, with only two patients experiencing non-toxicity-related delays. Outpatient administration reduced costs by approximately 10-15% compared to inpatient administration. Qualitative analysis revealed that while anticipated clinical challenges were effectively managed, practical aspects such as transportation and financial considerations emerged as primary patient concerns. One patient proceeded to conversion surgery, one discontinued due to financial constraints, and three continue treatment.Conclusion: Outpatient zolbetuximab administration proved safe and feasible in a community setting when implemented with appropriate protocols and support systems. This implementation model could serve as a template for delivering complex cancer therapies in resource-limited settings.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"951-960"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors Contributing to Blood Glucose Elevation Associated With Olanzapine Used as an Antiemetic During Cancer Chemotherapy.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13894

Yuko Kanbayashi, Takeshi Ishikawa, Tetsuya Taguchi, Koichi Takayama

{"title":"Factors Contributing to Blood Glucose Elevation Associated With Olanzapine Used as an Antiemetic During Cancer Chemotherapy.","authors":"Yuko Kanbayashi, Takeshi Ishikawa, Tetsuya Taguchi, Koichi Takayama","doi":"10.21873/invivo.13894","DOIUrl":"10.21873/invivo.13894","url":null,"abstract":"Background/aim: This retrospective study aimed to identify factors contributing to blood glucose elevation associated with olanzapine use and to develop new strategies involving olanzapine aimed at enhancing quality of life in patients undergoing chemotherapy.Patients and methods: This study enrolled 220 cancer patients undergoing chemotherapy between January 2017 and May 2022 at our outpatient chemotherapy center. Variables related to the development of olanzapine-associated blood glucose elevation were extracted from medical records for use in regression analysis. We assessed the severity of blood glucose elevation based on the most recent blood glucose level measured after the final administration of olanzapine. Random blood glucose levels were scored as follows: 0, <140 mg/dl; 1, 140-200 mg/dl; or 2, >200 mg/dl. Multivariate ordered logistic regression analysis was performed to identify potential factors in the development of blood glucose elevations associated with olanzapine.Results: Factors correlated with olanzapine-associated blood glucose elevation included pre-chemotherapy random blood glucose level (p=0.002), gastric cancer (p=0.003), and the use of calcium channel blockers (p=0.048). Although concomitant use of renin-angiotensin system inhibitors showed a tendency toward an association with elevated blood glucose levels, this finding was not statistically significant.Conclusion: Identifying potential factors contributing to olanzapine-associated blood glucose elevation may assist in developing strategies to improve quality of life for patients undergoing chemotherapy.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"902-908"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A New Approach to Highly Conformal Hippocampal-sparing Whole-brain Radiotherapy: A Feasibility Study.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13886

Christian Ziemann, Florian Cremers, Miller MacPherson, Dirk Rades, Anastassia Löser

{"title":"A New Approach to Highly Conformal Hippocampal-sparing Whole-brain Radiotherapy: A Feasibility Study.","authors":"Christian Ziemann, Florian Cremers, Miller MacPherson, Dirk Rades, Anastassia Löser","doi":"10.21873/invivo.13886","DOIUrl":"10.21873/invivo.13886","url":null,"abstract":"Background/aim: Hippocampal-sparing whole-brain radiotherapy (HS-WBRT) is increasingly used for multiple brain metastases. However, most studies have not reported dose conformity indices (CI). In the only study indicating the CI, conformity was low (CI=0.7). We developed a new technique to achieve a significantly higher CI and better dose coverage.Patients and methods: Ten patients received 30 Gy of HS-WBRT for brain metastases. Three variants of treatment plans (VAR1, VAR2, VAR3) were investigated. Volumetric modulated arc therapy plans with two (2ROT) or three rotations (3ROT) were created for each variant. Plans were compared for compliance with hippocampal sparing criteria, CI (where a higher value indicates better conformity), and homogeneity index (HI, where a lower value indicates better homogeneity).Results: Best results (highest CI, lowest HI) were achieved with the VAR3-3ROT technique (a new method), which yielded a CI=0.92-0.95 and a HI=0.05-0.09. VAR3-2ROT led to a CI=0.90-0.95 and a HI=0.06-0.11. With the other techniques, CI and HI ranged between 0.77-0.87 and 0.15-0.32, respectively.Conclusion: Our new technique achieved both appropriate hippocampal sparing and very high dose conformity of ≥0.9. Significant underdosage outside the hippocampal-sparing area was avoided.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"834-843"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of Pneumocystis jirovecii Pneumonia in Patients With HIV in Taiwan: Evidence from a Cross-sectional Study.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13910

Jiun-Yi Wang, Kuang-Hua Huang, Chih-Jaan Tai, Shuo-Yan Gau, Tung-Han Tsai, Chun-Nan Wu, Chien-Ying Lee

{"title":"Risk of Pneumocystis jirovecii Pneumonia in Patients With HIV in Taiwan: Evidence from a Cross-sectional Study.","authors":"Jiun-Yi Wang, Kuang-Hua Huang, Chih-Jaan Tai, Shuo-Yan Gau, Tung-Han Tsai, Chun-Nan Wu, Chien-Ying Lee","doi":"10.21873/invivo.13910","DOIUrl":"10.21873/invivo.13910","url":null,"abstract":"Background/aim: Studies have demonstrated that patients with HIV are at a higher risk of Pneumocystis jirovecii pneumonia (PJP). Epidemiological knowledge of the risk of PJP among patients with HIV infection is lacking. This study aimed to assess the risk of PJP among patients with HIV.Patients and methods: This cross-sectional study was conducted using the National Health Insurance Research Database of Taiwan. The participants were 18,929 patients with new-onset HIV infection from 2002 to 2015. Each patient was matched with four HIV-negative patients for age, sex, insured salary, urbanization status, Charlson Comorbidity Index score, and year of enrollment. The logistic regression with adjustment for relevant variables was performed to analyze the risk of PJP among patients with HIV at the 3-year follow-up. Sensitivity analysis was performed to compare the risk of PJP among different cohorts (patients with chronic kidney disease) and at different follow-up periods (6-month, 1-year, and 2-year follow-up).Results: Patients with HIV had a higher risk of PJP [adjusted odds ratio (aOR)=199.36; 95% confidence interval (CI)=119.47-332.66] than HIV-negative individuals at the 3-year follow-up. Male patients had a higher risk of PJP (aOR=1.62; 95%CI=1.18-2.24) than female patients. Patients with chronic obstructive pulmonary disease (COPD) had a higher risk of PJP (aOR=1.74; 95%CI=1.27-2.39) at the 3-year follow-up.Conclusion: Patients with HIV had a higher risk of PJP. Male patients had a higher risk of PJP than female patients. The risk of PJP was higher among patients with COPD.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1054-1066"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alginate Beads Encapsulating Hydroxyapatite Microparticle and BMP-2 for Long Bone Defect Regeneration: A Pilot Study.

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13877

Seoyun Lee, Honghyun Park, Hui-Suk Yun, Byung-Jae Kang

{"title":"Alginate Beads Encapsulating Hydroxyapatite Microparticle and BMP-2 for Long Bone Defect Regeneration: A Pilot Study.","authors":"Seoyun Lee, Honghyun Park, Hui-Suk Yun, Byung-Jae Kang","doi":"10.21873/invivo.13877","DOIUrl":"10.21873/invivo.13877","url":null,"abstract":"Background/aim: Large bone defects caused by trauma, infection, tumor excision, and non-union fractures are challenging to treat. Mechanical stability, appropriate osteoconductive bone grafts, and osteoinductive growth factors are necessary for bone regeneration in long bone diaphyseal defects. This study aimed to investigate the efficiency of a hybrid bone scaffold formed using hydroxyapatite (HAp) and bone morphogenetic protein (BMP)-2-containing alginate beads, combined with a barrier membrane, in promoting new bone formation in a rabbit radial segmental defect model.Materials and methods: Nine rabbits were divided into two groups depending on the type of implant: Alginate beads containing HAp microparticles in phosphate-buffered saline (n=5) or BMP-2 (n=4). A 10-mm radial segmental defect was stabilized using a bone plate and screws, wrapped with an absorbable collagen membrane, and filled with alginate beads. Bone healing at the defect site was assessed via radiography, micro-computed tomography, and histological analysis after 12 weeks.Results: The BMP-2/HAp alginate bead group showed significantly increased bone volume, polar moment of inertia, and periosteal callus ossification, along with a decreased fibrous infiltration at the defect site. Conversely, the BMP-2-unloaded HAp bead group exhibited membrane degradation, with no hard callus formation at the defect site. Therefore, HAp- and BMP-2-encapsulating alginate beads provided sufficient osteoconductive and osteoinductive support for long bone defect repair.Conclusion: BMP-2/HAp alginate beads, combined with an appropriate collagen membrane and proper internal fixation, may be an effective treatment strategy for long bone segmental defects.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"732-741"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0